Abstracts tagged "Antiphospholipid antibodies and pregnancy"

Abstract Number: 160 • 2018 ACR/ARHP Annual Meeting
Pregnancy Outcomes of Antiphospholipid Antibody Positive Patients: Prospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Ecem Sevim¹, Danieli Andrade², Alessandra Banzato³, Maria Tektonidou⁴, Amaia Ugarte⁵, Cecilia B. Chighizola⁶, Lanlan Ji⁷, David Branch⁸, Guilherme Ramires de Jesus⁹, Laura Andreoli¹⁰, Michelle Petri¹¹, Ricard Cervera¹², Jason S. Knight¹³, Tatsuya Atsumi¹⁴ and Doruk Erkan¹⁵, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ³Department of Cardiac Thoracic and Vascular Sciences, Clinical Cardiology, Thrombosis Centre, University of Padova, Padova, Italy, ⁴Rheumatology Unit, 1st Dept. of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, Athens University Medical School, Athens, Greece, ⁵Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Biscay, Spain, ⁶Rheumatology, Istituto Auxologico Italiano, University of Milan, Milan, Italy, ⁷Rheumatology and Immunology, Peking University First Hospital, Beijing, China., Beijing, China, ⁸Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, UT, ⁹Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁰Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ¹¹Johns Hopkins University School of Medicine, Baltimore, MD, ¹²Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic de Barcelona, Barcelona, Spain, ¹³., University of Michigan, Ann Arbor, MI, ¹⁴Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ¹⁵Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY
Background/Purpose: APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL) positive patients with or…
Abstract Number: 12 • 2017 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository Analysis: Pregnancy Outcomes Since Inception
Ecem Sevim¹, Danieli Andrade², Alessandra Banzato³, D. Ware Branch⁴, Ricard Cervera⁵, Guilherme Ramires de Jesus⁶, Jason S. Knight⁷, Pier Luigi Meroni⁸, Maria Tektonidou⁹, Angela Tincani¹⁰, Amaia Ugarte¹¹, Zhang Zhuoli¹², Doruk Erkan¹³ and , on Behalf of APS ACTION .¹⁴, ¹Umraniye Research and Training Hospital, Istanbul Health Sciences University, Istanbul, Turkey, ²Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., Sao Paulo, Brazil, ³Department of Cardiac Thoracic and Vascular Sciences, Clinical Cardiology, Thrombosis Centre, University of Padova, Padova, Italy, ⁴Obstetrics and Gynecology, University of Utah and Intermountain Healthcare, Salt Lake City, UT, ⁵Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic de Barcelona, Barcelona, Spain, ⁶Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁷., University of Michigan, Ann Arbor, MI, ⁸Istituto Ortopedico Gaetano Pini, University of Milan, Milano, Italy, ⁹First Department of Internal Medicine, School of Medicine, National University of Athens, Athens, Greece, ¹⁰Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ¹¹Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Biscay, Spain, ¹²Department of Rheumatology and Immunology,Peking University First Hospital, Peking University First Hospital, Beijing, China, ¹³Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ¹⁴., New York, NY
Background/Purpose: APS ACTION Clinical Database and Repository (‘‘Registry’’) was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)…
Abstract Number: 2530 • 2015 ACR/ARHP Annual Meeting
A Multicenter Evaluation of Obstetric and Maternal Outcome in Prospectively Followed Pregnant Patients with Confirmed Positivity for Antiphospholipid Antibodies (aPL)
Micaela Fredi¹, Elena Aggogeri², Elisa Bettiga³, Laura Andreoli², Maria Grazia Lazzaroni², Véronique Le Guern⁴, Andrea Lojacono³, Fabrizio Lupoli², Nathalie Morel⁴, Jean Charles Piette⁵, Sonia Zatti³, Nathalie Costedoat-Chalumeau⁴ and Angela Tincani², ¹Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ³Obstetrics and Gynecology, Spedali Civili and University of Brescia, Brescia, Italy, ⁴Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ⁵Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France
Background/Purpose: Antiphospholipd antibodies (aPL) positivity is considered as a risk factors for a poor obstetric outcome. The aim of this work was to determine risk…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].